Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database.

Respir Investig

Nippon Boehringer Ingelheim Co., Ltd., 2-1-1 Osaki, Shinagawa-ku, Tokyo, 141-6017, Japan.

Published: July 2024

AI Article Synopsis

  • This study focuses on interstitial lung diseases (ILDs) in Japan, specifically looking at the incidence of progressive pulmonary fibrosis (PPF) in patients with fibrosing ILDs that aren't idiopathic pulmonary fibrosis.
  • Data from nearly 35,000 patients revealed that 41.7% progressed to PPF within 24 months, with rates being similar across different ILD subtypes, and the most common treatments included oral corticosteroids and tacrolimus.
  • The findings highlight a significant prevalence of PPF progression in chronic fibrosing ILDs, emphasizing the need for future research on how regular monitoring and early treatment could improve patient outcomes.

Article Abstract

Background: Interstitial lung diseases (ILDs) are a heterogeneous group of disorders, a subset of which develop progressive pulmonary fibrosis (PPF). There is little information on the epidemiology and treatment of PPFs in Japan. This retrospective cohort study estimated the incidence probability of progression to PPFs in patients with fibrosing ILDs other than idiopathic pulmonary fibrosis in a real-world Japanese setting. Management procedures and treatment patterns were also quantified.

Methods: Data were extracted from the Medical Data Vision database from 01-Jan-2012 to 28-May-2020, comprising a 6.91-year patient identification period, 1-year pre-index period, and post-index period. The primary outcome was the cumulative incidence probability of progression to PPF up to 24 months. Subgroup analyses were performed by the presence/absence of connective tissue disease-ILD and by pre-specified ILD clinical diagnosis.

Results: Of the 34,960 eligible patients (mean age: 71.1 years, males: 52.5%), 14,580 (41.7%) progressed to PPF. The 24-month incidence probability of progression to PPF was 39.5%. A relatively comparable percentage of patients progressed across all ILD subtypes. Oral corticosteroids and tacrolimus were the most common therapies during the pre- and post-index periods. Treatment rates were very low in the post-index period.

Conclusions: This is the first claims database study to estimate the incidence probability of progression to PPF in Japan. Progression appeared common in patients with chronic fibrosing ILDs, with comparable percentages of patients across all subtypes developing PPF at 2 years. Future studies should assess the impact of regular monitoring and early intervention on treating fibrotic ILDs and preventing progression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.resinv.2024.05.005DOI Listing

Publication Analysis

Top Keywords

incidence probability
16
probability progression
16
pulmonary fibrosis
12
progression ppf
12
progressive pulmonary
8
fibrosis ppf
8
treatment rates
8
claims database
8
fibrosing ilds
8
ppf
7

Similar Publications

Uptake of Recommended Vaccines During Pregnancy Among Publicly and Privately Insured People in the United States, December 2020-September 2022.

Am J Public Health

January 2025

Stacey L. Rowe is with the School of Nursing and Health Professions, University of San Francisco, San Francisco, CA. Sheena G. Sullivan is with the School of Clinical Sciences, Monash University, Melbourne, Australia. Flor M. Munoz is with the Department of Pediatrics, Baylor College of Medicine, Houston, TX. Matthew M. Coates and Onyebuchi A. Arah are with the Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles. Annette K. Regan is with the Department of Research and Evaluation, Kaiser Permanente Research, Pasadena, CA.

To estimate maternal COVID-19, influenza, and pertussis vaccine uptake during pregnancy by insurance type and identify factors characterizing those vaccinated and unvaccinated. We conducted a US cohort study of pregnant individuals (for pregnancies ending December 11, 2020-September 30, 2022) using insurance claims data. We calculated vaccination probability using Kaplan-Meier methods and identified factors associated with vaccination through binomial regression with inverse probability weights.

View Article and Find Full Text PDF

Rationale: Although the guidelines generally omit routine antibiotic prophylaxis for diagnostic bronchoscopy, this recommendation is primarily based on studies with relatively small sample sizes conducted at single institutions. Moreover, the applicability of recent technical and procedural advancements to these guidelines remains uncertain.

Objectives: To evaluate whether oral prophylactic antibiotic administration for diagnostic bronchoscopy reduces post-bronchoscopy infections among non-infectious diseases in the current setting.

View Article and Find Full Text PDF

Background: Multiple studies across Ethiopia have investigated the occurrence of DKA, showing significant variations and conflicting findings. This systematic review and meta-analysis seek to consolidate the overall prevalence of diabetic ketoacidosis and its associated factors in the Ethiopian context.

Methods: The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) guidelines.

View Article and Find Full Text PDF

Background: Self-reported health problems following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are common and often include relatively non-specific complaints such as fatigue, exertional dyspnoea, concentration or memory disturbance and sleep problems. The long-term prognosis of such post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) is unknown, and data finding and correlating organ dysfunction and pathology with self-reported symptoms in patients with non-recovery from PCS is scarce. We wanted to describe clinical characteristics and diagnostic findings among patients with PCS persisting for >1 year and assessed risk factors for PCS persistence versus improvement.

View Article and Find Full Text PDF

Diarrhea is a global public health problem that is the third leading cause of death in under five years, with an estimated 1.7 billion cases in 2023 and 1.8 million deaths from diarrhea diseases every year.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!